Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| The combination of improvements across multiple circulating fibrosis related biomarkers and the positive FibroScan results is encouraging and add to the growing evidence that CM-101 may have the potential to be safe and effective treatments for fibro-inflammatory diseases such as NASH and PSC |
| I am pleased to report that we have continued to make good progress on multiple fronts since our last investor call |
| We believe we are doing a good job delivering on these goals |
| We believe we have made great progress towards demonstrating CM-101 in our clinical programs |
| Inhibition on the systemic sclerosis is strong |
| Overall, we were very pleased to see favorable pharmacokinetic target engagement profiles that are consistent with what we've seen in earlier studies |
| We're making good progress in advancing our CM-101 Phase 2 clinical program in PSC |
| We are pleased with a good productivity we have achieved by adding clinical sites and enhancing our patient outreach activities in line with our plans to report top line data from this trial in the second half of next year |
| We believe the results are encouraging |
| We also saw as expected an increase in target engagement in the CM-101-treated group indicating CM-101's robust and specific engagement with its target and a strong PK target engagement relationship |
| In summary, based on these four clinical trials of CM-101 completed to-date, we see that CM-101 is pretty safe in more than 70 healthy subjects and patients who have received it |
| Additionally, we believe that these results support the therapeutic potential of CM-101 across multiple organs and inflammatory fibrotic diseases and are especially encouraging in support of the prospects for our two main indications of primary sclerosing cholangitis or PSC and systemic sclerosis or SSc, two rare diseases that share some of the same fibro-inflammatory features as NASH |
| The CM-101 may have the potential to positively impact patients with a variety of fibro inflammatory diseases |
| In January, we reported encouraging top line results from our CM-101 Phase 2 liver fibrosis trial in patients with NASH |
| We are pleased at the progress of the PSC trial and remain on track to report top-line data from the double-blind portion in the second half of 2024 |
| Dale? Dale Pfost I hope, we've conveyed some of our enthusiasm about the momentum we are building at Chemomab |
| Matt brings us a wealth of global-pharma and biotech industry experience across all aspects of clinical development and medical affairs along with his outstanding track record in helping to bring numerous drugs to market in both rare and chronic diseases |
| We believe that a novel therapeutic that addresses various manifestations of the disease including the dermatological aspects would represent a major advance in the treatment of SSC |
| It has the highest mortality of all the systemic rheumatic diseases |
| We're now building upon our strong preclinical data package with this initial trial, but we see to confirm the critical role of CCL24 in this disease and to establish biological and clinical proof of concept of CM-101 in patients with SSC |
| CM-101 appeared safe |
| We've received some very encouraging data in NASH |
| And we feel it's an opportunity to ensure that we have the opportunity to expand that and focus on those patients who were being neglected as well |
| We are also pleased late last year when the independent drug monitoring committee conducted a review of CM-101 safety data and cleared us to add the planned 20 milligrams per kilogram dose arm to the PSC trial |
| These results from these clinical trials and multiple non-clinical studies showing groups of fibro-inflammatory markers moving in the same right direction along with physiological measures too increased our optimism about the potential for CM-101 as a treatment for fibro-inflammatory diseases |
| In this study, CM-101 appeared safe and demonstrated improvements across multiple disease-related fibrotic and inflammatory biomarkers |
| And the reason there is that when we worked with the FDA, we really felt that that's an opportunity to see the tissue effect and that's a viable way forward to do that demonstration in the Phase 2a program |
| Importantly, we are seeing consistent signals across these studies |
| Mitch who is an MD, PhD, has a rich combination of science and business skills that make him well qualified to lead the corporate development function at Chemomab |
| We believe that the data have been well received by opinion leaders working in NASH and other fibrotic diseases as well as by pharma firms with whom we are in ongoing dialogue |
| Statement |
|---|
| As you know the market for biotech stocks remains very challenging |
| Both patient populations suffered dramatically from the disease |
| Our net loss was $8.8 million or a net loss of approximately $0.04 per basic and diluted ordinary share for the first quarter of 2023, compared to $5.1 million or a net loss of approximately $0.02 per basic and diluted ordinary share for the quarter ended March 31 2022 |
| These statements are subject to risks and uncertainties that could cause our actual results to materially differ from those expressed or implied on today's call |
Please consider a small donation if you think this website provides you with relevant information